Azmi Nasser

A Phase III, Randomized, Placebo-controlled Trial to Assess the Efficacy and Safety of Once-daily SPN-812 (Viloxazine Extended-release) in the Treatment of Attention-deficit/Hyperactivity Disorder in School-age Children

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2020 · 83 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Sustained-Release Buprenorphine (RBP-6000) Blocks the Effects of Opioid Challenge With Hydromorphone in Subjects With Opioid Use Disorder

Azmi Nasser, Mark K. Greenwald, Bradley Vince et al. · Journal of Clinical Psychopharmacology · 2015 · 74 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

A Phase II Double-Blind, Placebo-Controlled, Efficacy and Safety Study of SPN-812 (Extended-Release Viloxazine) in Children With ADHD

Janet Johnson, Tesfaye Liranso, Keith E. Saylor et al. · Journal of Attention Disorders · 2019 · 61 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial

Azmi Nasser, Tesfaye Liranso, Toyin Adewole et al. · Clinical Therapeutics · 2021 · 53 citations

Medicine, Pediatrics, Pharmacotherapy +14

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder

Azmi Nasser, Joseph T. Hull, Soumya A. Chaturvedi et al. · CNS Drugs · 2022 · 52 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +17